We propose the Inflammatory Drug-Resistant Epilepsy Index (IDREI), a novel biomarker derived from plasma concentrations of ICAM-1, IL-4, and IL-10 and CSF levels of NfL, for the prediction of DRE. Here, NEFL is linked to epilepsy.